217314-45-9Relevant articles and documents
Macrocyclic inhibitors of β-secretase: Functional activity in an animal model
Stachel, Shawn J.,Coburn, Craig A.,Sankaranarayanan, Sethu,Price, Eric A.,Pietrak, Beth L.,Huang, Qian,Lineberger, Janet,Espeseth, Amy S.,Jin, Lixia,Ellis, Joan,Holloway, M. Katharine,Munshi, Sanjeev,Allison, Timothy,Hazuda, Daria,Simon, Adam J.,Graham, Samuel L.,Vacca, Joseph P.
, p. 6147 - 6150 (2007/10/03)
A macrocyclic inhibitor of β-secretase was designed by covalently cross-linking the P1 and P3 side chains of an isophthalamide-based inhibitor. Macrocyclization resulted in significantly improved potency and physical properties when compared to the initia
PYRROLIDIN-3-YL COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
Page/Page column 39, (2010/02/15)
The present invention is directed to pyrrolidin-3-yl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The i
1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
Page/Page column 69, (2010/02/14)
The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.